ACE-1755

N/A

Report date: 2022/09/05 17:20:15

Base Information

Drug NameACE-1755
Drug Alias NameACE-1755
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionAnti-CD19Natural killer cell replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAcepodia Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesAcepodia Biotech Inc
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A